379 related articles for article (PubMed ID: 29335623)
41. Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.
Berger K; Schopohl D; Rieger C; Ostermann H
Support Care Cancer; 2015 Dec; 23(12):3447-54. PubMed ID: 25773673
[TBL] [Abstract][Full Text] [Related]
42. The use of defibrotide in blood and marrow transplantation.
Richardson PG; Carreras E; Iacobelli M; Nejadnik B
Blood Adv; 2018 Jun; 2(12):1495-1509. PubMed ID: 29945939
[TBL] [Abstract][Full Text] [Related]
43. A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study.
Mohty M; Battista ML; Blaise D; Calore E; Cesaro S; Maximova N; Perruccio K; Renard C; Wynn R; Zecca M; Labopin M; Hanvesakul R; Amber V; Ryan RJ; Lawson S; Ciceri F
Bone Marrow Transplant; 2021 Oct; 56(10):2454-2463. PubMed ID: 34059801
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and Safety of Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Yang L; Qi J; Pan T; You T; Ruan C; Han Y
Semin Thromb Hemost; 2019 Nov; 45(8):767-777. PubMed ID: 31627217
[TBL] [Abstract][Full Text] [Related]
45. Veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East/North Africa regional consensus on prevention, diagnosis and management.
Al Jefri AH; Abujazar H; Al-Ahmari A; Al Rawas A; Al Zahrani Z; Alhejazi A; Bekadja MA; Ibrahim A; Lahoucine M; Ousia S; Bazarbachi A
Bone Marrow Transplant; 2017 Apr; 52(4):588-591. PubMed ID: 27892944
[TBL] [Abstract][Full Text] [Related]
46. Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation.
Coutsouvelis J; Avery S; Dooley M; Kirkpatrick C; Spencer A
Cancer Treat Rev; 2016 Nov; 50():200-204. PubMed ID: 27721142
[TBL] [Abstract][Full Text] [Related]
47. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
Diaz MA; Vicent MG; Madero L
Bone Marrow Transplant; 1999 Dec; 24(11):1157-9. PubMed ID: 10642802
[TBL] [Abstract][Full Text] [Related]
48. Treatment of Sinusoidal Obstruction Syndrome With Defibrotide in Pediatric Cancer Patients Following Nontransplant-associated Chemotherapy: A Case Report and Review of the Literature.
Lawrence MR; Bassal M; Ramphal R; Johnston DL
J Pediatr Hematol Oncol; 2022 Apr; 44(3):e788-e791. PubMed ID: 33902061
[TBL] [Abstract][Full Text] [Related]
49. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
[TBL] [Abstract][Full Text] [Related]
50. Late-onset hepatic veno-occlusive disease post autologous peripheral stem cell transplantation successfully treated with oral defibrotide.
Shah MS; Jeevangi NK; Joshi A; Khattry N
J Cancer Res Ther; 2009; 5(4):312-4. PubMed ID: 20160371
[TBL] [Abstract][Full Text] [Related]
51. Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.
Strouse C; Richardson P; Prentice G; Korman S; Hume R; Nejadnik B; Horowitz MM; Saber W
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1306-1312. PubMed ID: 27108694
[TBL] [Abstract][Full Text] [Related]
52. Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant.
Nauffal M; Kim HT; Richardson PG; Soiffer RJ; Antin JH; Cutler C; Nikiforow S; Gooptu M; Koreth J; Romee R; Ho VT
Blood Adv; 2022 Jan; 6(1):181-188. PubMed ID: 34666352
[TBL] [Abstract][Full Text] [Related]
53. Molecular Advances in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease.
Mavrikou I; Chatzidimitriou D; Skoura L; Nikolousis E; Sakellari I; Gavriilaki E
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982695
[TBL] [Abstract][Full Text] [Related]
54. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation in adult patients: Diagnosis, incidence, prophylaxis, and treatment.
Özkan HA; Özkan SG
Transfus Apher Sci; 2022 Feb; 61(1):103372. PubMed ID: 35101376
[TBL] [Abstract][Full Text] [Related]
55. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma.
Atra A; Whelan JS; Calvagna V; Shankar AG; Ashley S; Shepherd V; Souhami RL; Pinkerton CR
Bone Marrow Transplant; 1997 Nov; 20(10):843-6. PubMed ID: 9404924
[TBL] [Abstract][Full Text] [Related]
56. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
[TBL] [Abstract][Full Text] [Related]
57. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
[TBL] [Abstract][Full Text] [Related]
58. Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study.
Ruutu T; Peczynski C; Houhou M; Polge E; Mohty M; Kröger N; Moiseev I; Penack O; Salooja N; Schoemans H; Duarte RF; Schroeder T; Passweg J; Wulf GG; Ganser A; Sica S; Arat M; Salmenniemi U; Broers AEC; Bourhis JH; Rambaldi A; Maertens J; Halaburda K; Zuckerman T; Labussière-Wallet H; Basak G; Koenecke C; Perić Z
Bone Marrow Transplant; 2023 Nov; 58(11):1209-1214. PubMed ID: 37573397
[TBL] [Abstract][Full Text] [Related]
59. Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.
Kayser S; Sartor C; Giglio F; Bruno A; Webster J; Chiusolo P; Saraceni F; Guerzoni S; Pochintesta L; Borlenghi E; Marconi G; Zacheo I; Cerrano M; Salutari P; Restuccia F; Abbenante M; Levis MJ; Schlenk RF; Papayannidis C
Haematologica; 2024 May; 109(5):1385-1392. PubMed ID: 38058184
[TBL] [Abstract][Full Text] [Related]
60. Defibrotide Shows Efficacy in the Prevention of Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study.
Chalandon Y; Mamez AC; Giannotti F; Beauverd Y; Dantin C; Mahne E; Mappoura M; Bernard F; de Ramon Ortiz C; Stephan C; Morin S; Ansari M; Simonetta F; Masouridi-Levrat S
Transplant Cell Ther; 2022 Nov; 28(11):765.e1-765.e9. PubMed ID: 35953029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
